Development of an LC-MS method for the determination of simvastatin and its hydroxy acid form in muscle tissue and method application
PLOS One · 05.05.2025 · 20 (5) · e0322808
DOI: 10.1371/journal.pone.0322808 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 05.05.2025. Verfasst von Ewa Paszkowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical University of Lublin, Department of Bioanalytics, Lublin, Poland. Hauptthemen laut MEDLINE: Simvastatin, Mass Spectrometry, Muscles, Muscle, Skeletal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, Medical University of Bialystok, Poland.
Abstract (Originalsprache)
Purpose
Statins are the most commonly used drugs worldwide. Besides a significant decrease in cardiovascular diseases (CVDs) risk, the use of statins is also connected with a broad beneficial pleiotropic effect. At the same time, it is burdened with different side effects. The most common ones are muscle issues (from mild myalgia to rhabdomyolysis). The mechanisms of many of them are still unclear. Therefore, an analytical method for the determination of simvastatin (SIM) and its main metabolite (the hydroxy acid form – SIMA) in muscle tissue was developed.
Methods
Muscle samples were homogenized with ammonium acetate buffer using the bead mill homogenizer, and then statins were extracted with a mixture of methanol and ethanol. Prepared samples were analyzed with liquid chromatography (using a reverse-phase column with a gradient elution) combined with the mass spectrometer which was operated in a multiple reaction monitoring mode.
Results
The assay was linear over a 0.1–5 ng/mL range for both statin forms. Inter- and intra-day precision and accuracy were characterized. The method was considered precise (with the following relative standard deviation values: 6.0–6.9% for SIM, and 8.1–12.9% for SIMA) and accurate (with the following mean accuracies: 91.4–100.1% for SIM, and 102.2–115.4% for SIMA). The extraction efficiency was evaluated by recovery determination (76% for SIM, and 99% for SIMA). Moreover, the matrix effect was calculated with the following results: 87% for SIM, and 139% for SIMA. The proposed method was applied for SIM and SIMA determination in skeletal muscle tissues obtained from statin-treated patients.
Conclusion
The obtained results proved that the method may be a useful tool for explaining muscle effects related to statin therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical University of Lublin, Department of Bioanalytics, Lublin, Poland.
- Medical University of Bialystok, Metabolomics and Proteomics Laboratory, Clinical Research Centre, Bialystok, Poland.
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Xlab, Center for Healthy Aging, Copenhagen, Denmark.
ORCID-Profile: Ewa Paszkowska, Karolina Pietrowska
Förderung
- National Science Centre
- Medical University of Bialystok, Poland
Zitieren
APA
Paszkowska, E., Pietrowska, K., Larsen, S., Fornal, E., & Ciborowski, M. (2025). Development of an LC-MS method for the determination of simvastatin and its hydroxy acid form in muscle tissue and method application. PLOS One, 20(5), e0322808. https://doi.org/10.1371/journal.pone.0322808
Vancouver
Paszkowska E, Pietrowska K, Larsen S, Fornal E, Ciborowski M. Development of an LC-MS method for the determination of simvastatin and its hydroxy acid form in muscle tissue and method application. PLOS One. 2025;20(5):e0322808. doi:10.1371/journal.pone.0322808
BibTeX
@article{Paszkowska2025,
author = {Paszkowska, Ewa and Pietrowska, Karolina and Larsen, Steen and Fornal, Emilia and Ciborowski, Michał},
title = {Development of an LC-MS method for the determination of simvastatin and its hydroxy acid form in muscle tissue and method application},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {5},
pages = {e0322808},
doi = {10.1371/journal.pone.0322808}
}
EUVIMED